Page last updated: 2024-10-23

atenolol and Tachycardia

atenolol has been researched along with Tachycardia in 46 studies

Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.

Tachycardia: Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.

Research Excerpts

ExcerptRelevanceReference
"A double-blind, randomised, controlled trial of forty patients was carried out to determine if oral atenolol pretreatment would reduce the incidence of tachycardia during carotid endarterectomy performed under cervical plexus block."9.07Prevention of tachycardia with atenolol pretreatment for carotid endarterectomy under cervical plexus blockade. ( Cook, RJ; Davies, MJ; Dysart, RH; Scott, DA; Silbert, BS, 1992)
"The effect of single oral doses of atenolol (100 mg), metoprolol (100 mg), propranolol (40 mg), and placebo on exercise tachycardia and on heart rate and finger tremor responses to graded injections of isoproterenol was investigated in six normal subjects."9.05Effect of atenolol, metoprolol, and propranolol on isoproterenol-induced tremor and tachycardia in normal subjects. ( Perucca, E; Pickles, H; Richens, A, 1981)
"The effects of atenolol on ventricular arrhythmias were evaluated in 25 men with significant ventricular ectopy."9.05Reduction of ventricular arrhythmias by atenolol. ( Heng, MK; Zimmer, I, 1985)
" The aim was to validate heart rate as a pharmacodynamic endpoint under continuous isoprenaline-induced tachycardia by means of PK-PD modelling of S(-)-atenolol."7.74Pharmacokinetic-pharmacodynamic modelling of S(-)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint. ( Danhof, M; de Lange, EC; Freijer, J; van Steeg, TJ, 2007)
" Prior to diagnosis, the patient was treated with a selective beta 1 blocker, atenolol, which resulted in suppression of the dysrhythmia and amelioration of the hypertension."7.68Pheochromocytoma associated ventricular tachycardia blocked with atenolol. ( Hays, JH; Michaels, RD; O'Brian, JT; Shakir, KM, 1990)
" The effect of tachycardia on right atrial pressure (RAP) and dimensions (RAD) and plasma immunoreactive atrial natriuretic factor (IR-ANF) was examined in anaesthetized rabbits before and after the administration of atenolol."7.68The effect of tachycardia on right atrial dynamics and plasma atrial natriuretic factor in anaesthetized rabbits. ( King, KA; Ledsome, JR, 1990)
"5) diagnostic His bundle studies incorporating programmed atrial and ventricular pacing for the induction of tachycardias was performed before and after betablockade with the cardioselective betablocking agent atenolol, in a dose of 5 mg given iv."7.66Antiarrhythmic effects of acute betablockade with atenolol on supraventricular tachycardias at rest and during exercise. ( Behrenbeck, DW; Braun, V; Gil-Sanchez, D; Hilger, HH; Hombach, V; Höpp, HW; Tauchert, M, 1981)
"Exercise tachycardia was monitored for 84 hours after administration of the drugs to monitor beta blockade in vivo."6.66Reduction of exercise tachycardia in man after propranolol, atenolol and bisoprolol in comparison to beta-adrenoceptor occupancy. ( Belz, GG; Butzer, R; Palm, D; Pett, B; Polsak, R; Wellstein, A, 1987)
"Ischemia-induced arrhythmias were studied during a 30 min period of occlusion of the left anterior descending (LAD) coronary artery, and 100% of control animals (n = 24) exhibited ventricular tachycardia and 63% ventricular fibrillation."5.27Ischemia- and reperfusion-induced arrhythmias in conscious rats--studies with prazosin and atenolol. ( Braimbridge, MV; Hearse, DJ; Kinoshita, K; Manning, AS, 1988)
"A double-blind, randomised, controlled trial of forty patients was carried out to determine if oral atenolol pretreatment would reduce the incidence of tachycardia during carotid endarterectomy performed under cervical plexus block."5.07Prevention of tachycardia with atenolol pretreatment for carotid endarterectomy under cervical plexus blockade. ( Cook, RJ; Davies, MJ; Dysart, RH; Scott, DA; Silbert, BS, 1992)
"The effect of single oral doses of atenolol (100 mg), metoprolol (100 mg), propranolol (40 mg), and placebo on exercise tachycardia and on heart rate and finger tremor responses to graded injections of isoproterenol was investigated in six normal subjects."5.05Effect of atenolol, metoprolol, and propranolol on isoproterenol-induced tremor and tachycardia in normal subjects. ( Perucca, E; Pickles, H; Richens, A, 1981)
"1 Differences in ability to attenuate isoprenaline tachycardia between the cardioselective beta-adrenoceptor antagonist atenolol and the non-selective drug propranolol, when administered in equivalent anti-exercise tachycardia oral doses, were measured in four normal volunteers."5.05Observations on the mechanism underlying the differences in exercise and isoprenaline tachycardia after cardioselective and non-selective beta-adrenoceptor antagonists. ( McGibney, D; Silke, B; Singleton, W; Taylor, SH, 1983)
"The effects of atenolol on ventricular arrhythmias were evaluated in 25 men with significant ventricular ectopy."5.05Reduction of ventricular arrhythmias by atenolol. ( Heng, MK; Zimmer, I, 1985)
"The comparative potency of two beta-blockers, propranolol and atenolol, in the inhibition of exercise tachycardia and isoproterenol-tachycardia has been studied in two groups of hypertensive patients, using oral doses which were increased weekly."5.04Comparative potency of atenolol and propranolol as beta-adrenergic blocking agents in man. ( Amery, A; De Plaen, JF; Reybrouck, T, 1976)
" The aim was to validate heart rate as a pharmacodynamic endpoint under continuous isoprenaline-induced tachycardia by means of PK-PD modelling of S(-)-atenolol."3.74Pharmacokinetic-pharmacodynamic modelling of S(-)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint. ( Danhof, M; de Lange, EC; Freijer, J; van Steeg, TJ, 2007)
"Our aim was primarily to assess whether or not a vagal tachycardia can be elicited in vivo without administration of atropine, and secondly to evaluate whether the dose of atropine, a muscarinic antagonist, determines the magnitude of the tachycardia."3.73An investigation into the physiological relevance of the vagal tachycardia in the anaesthetized dog. ( Markos, F; Snow, HM, 2006)
" Increasing doses (25 pmol - 1 nmol) of selective agonists at NK(1) ([Sar(9),Met(O(2))(11)]SP), NK(2) ([beta-Ala(8)]NKA(4 - 10)) and NK(3) (senktide) receptors into the SN produced tachycardia which was selectively and reversibly blocked by the prior injection of tachykinin antagonists at NK(1) (RP67580, 250 pmol), NK(2) (SR48968, 250 pmol) and NK(3) (R-820, 500 pmol) receptor."3.71Modulation of cardiac activity by tachykinins in the rat substantia nigra. ( Couture, R; Lessard, A, 2001)
" Atenolol neither modified HR nor BP variability in rats with hyperthyroidism."3.70Autonomic contribution to the blood pressure and heart rate variability changes in early experimental hyperthyroidism. ( Elghozi, JL; Laude, D; Ponchon, P; Safa-Tisseront, V, 1998)
"This study demonstrates that the tachycardia produced by systemic injections of the beta-adrenoceptor agonist, isoproterenol (10 microg/kg, i."3.70In vivo evidence that isoproterenol may increase heart rate in the rat by mechanisms in addition to activation of cardiac beta(1)- or beta(2)-adrenoceptors. ( Lewis, SJ; Whalen, EJ, 1999)
" Prior to diagnosis, the patient was treated with a selective beta 1 blocker, atenolol, which resulted in suppression of the dysrhythmia and amelioration of the hypertension."3.68Pheochromocytoma associated ventricular tachycardia blocked with atenolol. ( Hays, JH; Michaels, RD; O'Brian, JT; Shakir, KM, 1990)
" The effect of tachycardia on right atrial pressure (RAP) and dimensions (RAD) and plasma immunoreactive atrial natriuretic factor (IR-ANF) was examined in anaesthetized rabbits before and after the administration of atenolol."3.68The effect of tachycardia on right atrial dynamics and plasma atrial natriuretic factor in anaesthetized rabbits. ( King, KA; Ledsome, JR, 1990)
"Intoxication with metaproterenol, a mainly beta-2 selective agonist, was diagnosed in a dog with tachycardia, tachypnea, weakness, vomiting, and a history of exposure to the drug."3.68Metaproterenol intoxication in a dog. ( Keene, BW; Rush, JE, 1990)
"5) diagnostic His bundle studies incorporating programmed atrial and ventricular pacing for the induction of tachycardias was performed before and after betablockade with the cardioselective betablocking agent atenolol, in a dose of 5 mg given iv."3.66Antiarrhythmic effects of acute betablockade with atenolol on supraventricular tachycardias at rest and during exercise. ( Behrenbeck, DW; Braun, V; Gil-Sanchez, D; Hilger, HH; Hombach, V; Höpp, HW; Tauchert, M, 1981)
" Beta-blocker use at the 2 dosage levels was associated with significant improvement in survival compared with the nonuse of beta blockers (hazard ratios 0."2.71Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II). ( Andrews, M; Brodine, WN; Daubert, JP; Hall, WJ; Hockstad, ES; Lee, JK; McNitt, S; Moss, AJ; Tung, RT; Zareba, W, 2005)
"Exercise tachycardia was monitored for 84 hours after administration of the drugs to monitor beta blockade in vivo."2.66Reduction of exercise tachycardia in man after propranolol, atenolol and bisoprolol in comparison to beta-adrenoceptor occupancy. ( Belz, GG; Butzer, R; Palm, D; Pett, B; Polsak, R; Wellstein, A, 1987)
"Atenolol was discontinued because of adverse effects in 12 patients."2.66Atenolol for ventricular ectopy: a dose-response study. ( Fenster, PE; Goldman, S; Horwitz, LD; Lazzara, R; Marcus, FI; Morrison, D; Reynolds, D; Serokman, R; Thadani, U, 1987)
" We previously demonstrated that Ang II combined with evolving cardiodepression (48-hour tachycardia pacing, 48hP) induces marked chamber stiffening and increases metalloproteinases (MMPs)."1.31beta-blockade prevents sustained metalloproteinase activation and diastolic stiffening induced by angiotensin II combined with evolving cardiac dysfunction. ( Crow, MT; Gluzband, YA; Janicki, JS; Kass, DA; Lindsey, ML; Paolocci, N; Senzaki, H, 2000)
"Isoflurane caused an increase in HR at 0."1.29Effects of isoflurane on cardiovascular system and sympathovagal balance in New Zealand white rabbits. ( Grigioni, M; Marano, G; Tiburzi, F; Vergari, A; Zanghi, F, 1996)
"73 patients (89%) had ventricular extrasystoles in the 24 hour ambulatory ECG, 33 (40%) of them with an average of more than 30/h."1.27[Prevalence, therapeutic modification and prognostic significance of ventricular arrhythmias in the mitral valve prolapse syndrome]. ( Kafka, W, 1985)
"Ischemia-induced arrhythmias were studied during a 30 min period of occlusion of the left anterior descending (LAD) coronary artery, and 100% of control animals (n = 24) exhibited ventricular tachycardia and 63% ventricular fibrillation."1.27Ischemia- and reperfusion-induced arrhythmias in conscious rats--studies with prazosin and atenolol. ( Braimbridge, MV; Hearse, DJ; Kinoshita, K; Manning, AS, 1988)

Research

Studies (46)

TimeframeStudies, this research(%)All Research%
pre-199017 (36.96)18.7374
1990's11 (23.91)18.2507
2000's15 (32.61)29.6817
2010's3 (6.52)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fassini, A1
Resstel, LB2
Corrêa, FM2
Selen, DJ1
Gilbert, MP1
Kurnik, D2
Li, C2
Sofowora, GG2
Friedman, EA2
Muszkat, M2
Xie, HG1
Harris, PA1
Williams, SM1
Nair, UB1
Wood, AJ2
Stein, CM2
Gopinathannair, R1
Sullivan, RM1
Olshansky, B1
Cunningham, AJ1
Kohli, U1
Menon, UB1
Palatini, P1
Good, L1
Côté, E1
Wright, KN1
Brodine, WN1
Tung, RT1
Lee, JK1
Hockstad, ES1
Moss, AJ1
Zareba, W1
Hall, WJ1
Andrews, M1
McNitt, S1
Daubert, JP1
Hogan, K1
Markos, F3
Snow, HM2
van Steeg, TJ1
Freijer, J1
Danhof, M1
de Lange, EC1
Ngampramuan, S1
Baumert, M1
Beig, MI1
Kotchabhakdi, N1
Nalivaiko, E1
Gould, S1
Westwood, FR1
Curwen, JO1
Ashton, SE1
Roberts, DW1
Lovick, SC1
Ryan, AJ1
Ajala, AM1
Goodwin, JA1
Goodwin, SR1
Josephson, GD1
Laakso, M1
Pentikäinen, PJ1
Pyörälä, K1
Neuvonen, PJ1
Perucca, E1
Pickles, H1
Richens, A1
McGibney, D1
Singleton, W1
Silke, B1
Taylor, SH1
Montenero, AS1
Frustaci, A1
Gianolla, F1
Pennestri, F1
Santarelli, P1
Bellocci, F1
Rasmussen, K1
Andersen, K1
Wang, H1
Hombach, V1
Braun, V1
Höpp, HW1
Gil-Sanchez, D1
Behrenbeck, DW1
Tauchert, M1
Hilger, HH1
Steyer, M1
Poleska, W1
Diemer, HP1
Schmidt, H1
Heidenreich, J1
Kumagai, K1
Suzuki, H1
Ichikawa, M1
Jimbo, M1
Nishizawa, M1
Ryuzaki, M1
Saruta, T1
Marano, G1
Grigioni, M1
Tiburzi, F1
Vergari, A1
Zanghi, F1
Grubb, BP1
Kosinski, DJ1
Boehm, K1
Kip, K1
Safa-Tisseront, V1
Ponchon, P1
Laude, D1
Elghozi, JL1
Kuznetsov, AS1
Orme, S1
Channer, KS1
Whalen, EJ1
Lewis, SJ1
Senzaki, H1
Paolocci, N1
Gluzband, YA1
Lindsey, ML1
Janicki, JS1
Crow, MT1
Kass, DA1
Lessard, A1
Couture, R1
Schley, G2
Beckmann, R1
Hengstebeck, W1
De Plaen, JF1
Amery, A1
Reybrouck, T1
Abendroth, RR1
Meesmann, W1
Stephan, K1
Hübner, H1
Davies, MJ1
Dysart, RH1
Silbert, BS1
Scott, DA1
Cook, RJ1
Michaels, RD1
Hays, JH1
O'Brian, JT1
Shakir, KM1
King, KA1
Ledsome, JR2
Rush, JE1
Keene, BW1
Kafka, W1
Rankin, AJ1
Courneya, CA1
Wilson, N1
Wellstein, A1
Palm, D1
Belz, GG1
Butzer, R1
Polsak, R1
Pett, B1
Uprichard, AC1
Harron, DW1
Kinoshita, K1
Hearse, DJ1
Braimbridge, MV1
Manning, AS1
Fenster, PE1
Reynolds, D1
Horwitz, LD1
Morrison, D1
Goldman, S1
Thadani, U1
Lazzara, R1
Serokman, R1
Marcus, FI1
Heng, MK1
Zimmer, I1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Genetic Determinants of Response to Beta Blockade[NCT00837902]154 participants (Actual)Interventional2009-01-31Completed
Essential Arterial Hypotension and Allostasis Registry[NCT02018497]5,000 participants (Anticipated)Observational [Patient Registry]1995-01-31Recruiting
A Double-Blinded, Placebo-Controlled Study To Assess Hemodynamic Changes, Orthostatic Tolerance, Out-Patient Fatigue And Quality Of Life In Neuropathic And Non-Neuropathic POTS Patients In Response To Adrenoreceptor Agonist And Antagonist[NCT03070730]Phase 1/Phase 28 participants (Actual)Interventional2011-08-15Terminated (stopped due to Recruitment was slow and subjects declined participation after signing the ICF.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Reduction in Heart Rate

Reduction in heart rate based upon genotype while exercising. Participants exercised on a recumbent bike for 2 minutes at 25W, 2 minutes at 50W, and 2 minutes at 75W twice, once before taking atenolol, and once 2.5 hours after oral administration of 25 mg of atenolol. Data points represent unadjusted mean reduction in heart rate in the 3 genotype groups. (NCT00837902)
Timeframe: 2 exercise periods of 6 minutes each. 6 minutes of exercise before taking atenolol, and 6 minutes of exercise starting 2.5 hours after taking 25 mg of atenolol (2.5 hours + 6 minutes)

,,
Interventionbeats per minute (Mean)
0, baseline2 minutes from baseline, 2 minutes exercise at 25W4 minutes from baseline, 2 minutes exercise at 50W6 minutes from baseline, 2 minutes exercise at 75W
GLN/GLN7.99.611.714
GLN/LEU68.410.912.4
LEU/LEU3.37.49.110

Change in Blood Pressure From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Blood Pressure From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Blood Pressure From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline

A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: 2 weeks after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline

A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: 2 weeks after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline

A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: up to 3 days after randomization

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Heart Rate From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Heart Rate From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Heart Rate From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Maximal Postural Tachycardia During Tilt

Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: Up to 3 days after randomization

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Muscle Sympathetic Nerve Activity From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Muscle Sympathetic Nerve Activity From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Muscle Sympathetic Nerve Activity From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline

"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline

"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline

"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- HADS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- HADS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- HADS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-CIS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-CIS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-CIS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-EuroQOL From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-EuroQOL From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-EuroQOL From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-FSS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-FSS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-FSS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-MFI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-MFI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-MFI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-OI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-OI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-OI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-SF-36 Q From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-SF-36 Q From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-SF-36 Q From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Vascular Resistance From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Vascular Resistance From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Vascular Resistance From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change Maximal Postural Tachycardia During Tilt

Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: 2 weeks after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change Maximal Postural Tachycardia During Tilt

Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: 2 weeks after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Trials

8 trials available for atenolol and Tachycardia

ArticleYear
Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II).
    The American journal of cardiology, 2005, Sep-01, Volume: 96, Issue:5

    Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Carbazoles; Carvedilol; Defibrillators, Implantable; Fe

2005
Effect of atenolol, metoprolol, and propranolol on isoproterenol-induced tremor and tachycardia in normal subjects.
    Clinical pharmacology and therapeutics, 1981, Volume: 29, Issue:4

    Topics: Adult; Atenolol; Blood Pressure; Heart Rate; Humans; Male; Metoprolol; Physical Exertion; Propanolam

1981
Observations on the mechanism underlying the differences in exercise and isoprenaline tachycardia after cardioselective and non-selective beta-adrenoceptor antagonists.
    British journal of clinical pharmacology, 1983, Volume: 15, Issue:1

    Topics: Adult; Atenolol; Heart Rate; Humans; Isoproterenol; Male; Middle Aged; Physical Exertion; Propanolam

1983
Comparative potency of atenolol and propranolol as beta-adrenergic blocking agents in man.
    European journal of clinical pharmacology, 1976, Sep-30, Volume: 10, Issue:5

    Topics: Adult; Atenolol; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation; Female

1976
Prevention of tachycardia with atenolol pretreatment for carotid endarterectomy under cervical plexus blockade.
    Anaesthesia and intensive care, 1992, Volume: 20, Issue:2

    Topics: Aged; Atenolol; Bradycardia; Cervical Plexus; Creatine Kinase; Double-Blind Method; Electrocardiogra

1992
Reduction of exercise tachycardia in man after propranolol, atenolol and bisoprolol in comparison to beta-adrenoceptor occupancy.
    European heart journal, 1987, Volume: 8 Suppl M

    Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Bisoprolol; Double-Blind Method; Exercise Test; Heart

1987
Atenolol for ventricular ectopy: a dose-response study.
    Clinical pharmacology and therapeutics, 1987, Volume: 41, Issue:1

    Topics: Adult; Aged; Ambulatory Care; Arrhythmias, Cardiac; Atenolol; Circadian Rhythm; Dose-Response Relati

1987
Reduction of ventricular arrhythmias by atenolol.
    American heart journal, 1985, Volume: 109, Issue:6

    Topics: Adult; Aged; Arrhythmias, Cardiac; Atenolol; Heart Ventricles; Humans; Male; Middle Aged; Tachycardi

1985

Other Studies

38 other studies available for atenolol and Tachycardia

ArticleYear
Prelimbic cortex GABA
    Stress (Amsterdam, Netherlands), 2016, Volume: 19, Issue:6

    Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Bicuculline; Blood Pressure; GABA Antagonists; Limbi

2016
Nausea/vomiting · tachycardia · unintentional weight loss · Dx?
    The Journal of family practice, 2017, Volume: 66, Issue:2

    Topics: Adult; Antithyroid Agents; Atenolol; Female; Humans; Hyperthyroidism; Methimazole; Nausea; Pulmonary

2017
Beta-1-adrenoceptor genetic variants and ethnicity independently affect response to beta-blockade.
    Pharmacogenetics and genomics, 2008, Volume: 18, Issue:10

    Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Adult; Atenolol; Black People;

2008
Slower heart rates for healthy hearts: time to redefine tachycardia?
    Circulation. Arrhythmia and electrophysiology, 2008, Volume: 1, Issue:5

    Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno

2008
GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta(1)-adrenergic blockade in humans.
    Pharmacogenomics, 2009, Volume: 10, Issue:10

    Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Adult; Alleles; Atenolol; Black

2009
Elevated heart rate in hypertension: a target for treatment?
    Journal of the American College of Cardiology, 2010, Mar-02, Volume: 55, Issue:9

    Topics: Anti-Arrhythmia Agents; Atenolol; Heart Rate; Humans; Hypertension; Tachycardia; Treatment Outcome

2010
ECG of the month. Narrow-complex monomorphic tachycardia with a ventricular rate of 320 beats/min.
    Journal of the American Veterinary Medical Association, 2002, Oct-15, Volume: 221, Issue:8

    Topics: Animals; Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Diagnosis, Differential; Digoxin; Do

2002
Pressor and tachycardic responses evoked by microinjections of L-glutamate into the medial prefrontal cortex of unanaesthetized rats.
    The European journal of neuroscience, 2005, Volume: 21, Issue:9

    Topics: Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Corpus Callosum; Glutamic Acid; Gyrus Ci

2005
An investigation into the presence of a vagal tachycardia and the effect of vasoactive intestinal polypeptide on rat heart rate in vitro.
    Pharmacology, 2006, Volume: 76, Issue:2

    Topics: Animals; Anti-Arrhythmia Agents; Atenolol; Atropine; Dose-Response Relationship, Drug; Electric Stim

2006
An investigation into the physiological relevance of the vagal tachycardia in the anaesthetized dog.
    Acta physiologica (Oxford, England), 2006, Volume: 186, Issue:3

    Topics: Animals; Atenolol; Atropine; Blood Pressure; Dogs; Dose-Response Relationship, Drug; Electric Stimul

2006
Vagal postganglionic origin of vasoactive intestinal polypeptide (VIP) mediating the vagal tachycardia.
    European journal of applied physiology, 2006, Volume: 98, Issue:4

    Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Blood Pressure; Cardiac Catheterization; Coronary Ve

2006
Pharmacokinetic-pharmacodynamic modelling of S(-)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint.
    British journal of pharmacology, 2007, Volume: 151, Issue:3

    Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Algorithms; Animals; Atenolol; Dose-Response

2007
Activation of 5-HT(1A) receptors attenuates tachycardia induced by restraint stress in rats.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2008, Volume: 294, Issue:1

    Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Atenolol; Dose-Response Relationship, Drug; Heart R

2008
Effect of pretreatment with atenolol and nifedipine on ZD6126-induced cardiac toxicity in rats.
    Journal of the National Cancer Institute, 2007, Nov-21, Volume: 99, Issue:22

    Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Antineoplasti

2007
Undiagnosed Graves' Disease contributing to sleep disordered breathing in a child undergoing adenotonsillectomy.
    Paediatric anaesthesia, 2008, Volume: 18, Issue:4

    Topics: Acetaminophen; Adenoidectomy; Adenoids; Analgesics, Non-Narcotic; Analgesics, Opioid; Antihypertensi

2008
Prolongation of the Q-T interval caused by sotalol--possible association with ventricular tachyarrhythmias.
    European heart journal, 1981, Volume: 2, Issue:4

    Topics: Adrenergic beta-Antagonists; Atenolol; Electrocardiography; Heart Ventricles; Humans; Kinetics; Male

1981
[Clinical, electrophysiologic and histologic findings in a case of substained idiopathic ventricular tachycardia].
    Cardiologia (Rome, Italy), 1982, Volume: 27, Issue:12

    Topics: Adult; Atenolol; Biopsy; Electrocardiography; Heart Ventricles; Humans; Male; Myocardium; Tachycardi

1982
Atrial fibrillation induced by atenolol.
    European heart journal, 1982, Volume: 3, Issue:3

    Topics: Adult; Aged; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Electrocardiography; Female; Human

1982
Antiarrhythmic effects of acute betablockade with atenolol on supraventricular tachycardias at rest and during exercise.
    Klinische Wochenschrift, 1981, Feb-02, Volume: 59, Issue:3

    Topics: Adult; Aged; Anti-Arrhythmia Agents; Atenolol; Cardiac Pacing, Artificial; Electric Stimulation; Ele

1981
Combined use of beta-sympathomimetic drugs and beta-blockers during labour.
    Archives of gynecology, 1981, Volume: 230, Issue:3

    Topics: Atenolol; Blood Pressure; Ethanolamines; Female; Fenoterol; Heart Rate; Humans; Metoprolol; Obstetri

1981
Comparison of early and late start of antihypertensive agents and baroreceptor reflexes.
    Hypertension (Dallas, Tex. : 1979), 1996, Volume: 27, Issue:2

    Topics: Aging; Animals; Antihypertensive Agents; Atenolol; Baroreflex; Blood Pressure; Enalapril; Heart Rate

1996
Effects of isoflurane on cardiovascular system and sympathovagal balance in New Zealand white rabbits.
    Journal of cardiovascular pharmacology, 1996, Volume: 28, Issue:4

    Topics: Anesthetics, Inhalation; Animals; Atenolol; Baroreflex; Blood Pressure; Cardiovascular Physiological

1996
The postural orthostatic tachycardia syndrome: a neurocardiogenic variant identified during head-up tilt table testing.
    Pacing and clinical electrophysiology : PACE, 1997, Volume: 20, Issue:9 Pt 1

    Topics: Adult; Atenolol; Autonomic Nervous System Diseases; Erythropoietin; Female; Fludrocortisone; Humans;

1997
The postural orthostatic tachycardia syndrome: a neurocardiogenic variant identified during head-up tilt table testing.
    Pacing and clinical electrophysiology : PACE, 1997, Volume: 20, Issue:9 Pt 1

    Topics: Adult; Atenolol; Autonomic Nervous System Diseases; Erythropoietin; Female; Fludrocortisone; Humans;

1997
The postural orthostatic tachycardia syndrome: a neurocardiogenic variant identified during head-up tilt table testing.
    Pacing and clinical electrophysiology : PACE, 1997, Volume: 20, Issue:9 Pt 1

    Topics: Adult; Atenolol; Autonomic Nervous System Diseases; Erythropoietin; Female; Fludrocortisone; Humans;

1997
The postural orthostatic tachycardia syndrome: a neurocardiogenic variant identified during head-up tilt table testing.
    Pacing and clinical electrophysiology : PACE, 1997, Volume: 20, Issue:9 Pt 1

    Topics: Adult; Atenolol; Autonomic Nervous System Diseases; Erythropoietin; Female; Fludrocortisone; Humans;

1997
Autonomic contribution to the blood pressure and heart rate variability changes in early experimental hyperthyroidism.
    Journal of hypertension, 1998, Volume: 16, Issue:12 Pt 2

    Topics: Animals; Atenolol; Atropine; Autonomic Nervous System; Blood Pressure; Cardiomegaly; Disease Models,

1998
[The treatment of tachy-systolic fibrillation in a patient after aortocoronary shunting].
    Klinichna khirurhiia, 1999, Issue:2

    Topics: Anti-Arrhythmia Agents; Arteriovenous Shunt, Surgical; Atenolol; Atrial Fibrillation; Humans; Male;

1999
Tachycardia following low-tension electrocution.
    Postgraduate medical journal, 1999, Volume: 75, Issue:885

    Topics: Adenosine; Adult; Anti-Arrhythmia Agents; Atenolol; Atrioventricular Node; Electric Injuries; Electr

1999
In vivo evidence that isoproterenol may increase heart rate in the rat by mechanisms in addition to activation of cardiac beta(1)- or beta(2)-adrenoceptors.
    European journal of pharmacology, 1999, Oct-15, Volume: 382, Issue:3

    Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Atenolol; Biological Clocks; Drug In

1999
beta-blockade prevents sustained metalloproteinase activation and diastolic stiffening induced by angiotensin II combined with evolving cardiac dysfunction.
    Circulation research, 2000, Apr-14, Volume: 86, Issue:7

    Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Angiotensin II; Animals; Atenolol; Diastole;

2000
Modulation of cardiac activity by tachykinins in the rat substantia nigra.
    British journal of pharmacology, 2001, Volume: 134, Issue:8

    Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Atropine; Benzamides; Blood Pressure; Hemodynamics;

2001
[The treatment of acute cardiac dysrhythmias with atenolol (Tenormin) particularly after myocardial infarction (author's transl)].
    Zeitschrift fur Kardiologie, 1978, Volume: 67, Issue:4

    Topics: Acute Disease; Adult; Aged; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Atrial Flutter; Car

1978
[Effects of the beta-blocking agent atenolol on arrhythmias especially ventricular fibrillation and fibrillation threshold after acute experimental coronary artery occlusion (author's transl)].
    Zeitschrift fur Kardiologie, 1977, Volume: 66, Issue:7

    Topics: Animals; Arrhythmias, Cardiac; Atenolol; Carotid Arteries; Coronary Disease; Coronary Vessels; Dogs;

1977
Pheochromocytoma associated ventricular tachycardia blocked with atenolol.
    Journal of endocrinological investigation, 1990, Volume: 13, Issue:11

    Topics: Adrenal Gland Neoplasms; Adult; Atenolol; Dopamine; Electrocardiography; Epinephrine; Humans; Hypert

1990
The effect of tachycardia on right atrial dynamics and plasma atrial natriuretic factor in anaesthetized rabbits.
    The Journal of physiology, 1990, Volume: 422

    Topics: Anesthesia, Intravenous; Animals; Atenolol; Atrial Natriuretic Factor; Blood Pressure; Heart; Heart

1990
Metaproterenol intoxication in a dog.
    Journal of the American Veterinary Medical Association, 1990, Nov-15, Volume: 197, Issue:10

    Topics: Animals; Arrhythmias, Cardiac; Atenolol; Dog Diseases; Dogs; Echocardiography; Electrocardiography;

1990
[Prevalence, therapeutic modification and prognostic significance of ventricular arrhythmias in the mitral valve prolapse syndrome].
    Zeitschrift fur Kardiologie, 1985, Volume: 74, Issue:4

    Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Atenolol; Cardiac Complexes, Premature; Electrocardio

1985
Tachycardia releases atrial natriuretic peptide in the anesthetized rabbit.
    Life sciences, 1986, May-26, Volume: 38, Issue:21

    Topics: Acetylcholine; Animals; Atenolol; Atrial Natriuretic Factor; Atropine; Blood Pressure; Cardiac Pacin

1986
Atenolol, but not mexiletine, protects against stimulus-induced ventricular tachycardia in a chronic canine model.
    British journal of pharmacology, 1989, Volume: 96, Issue:1

    Topics: Animals; Anti-Arrhythmia Agents; Atenolol; Blood Pressure; Coronary Circulation; Disease Models, Ani

1989
Ischemia- and reperfusion-induced arrhythmias in conscious rats--studies with prazosin and atenolol.
    Japanese circulation journal, 1988, Volume: 52, Issue:12

    Topics: Animals; Arrhythmias, Cardiac; Atenolol; Blood Pressure; Coronary Disease; Heart Rate; Male; Myocard

1988